What 5 Analyst Ratings Have To Say About Dianthus Therapeutics
Across the recent three months, 5 analysts have shared their insights on Dianthus Therapeutics (NASDAQ:DNTH), expressing a variety of opinions spanning from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 3 | 0 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 1 | 1 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 1 | 1 | 0 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $38.2, along with a high estimate of $51.00 and a low estimate of $24.00. This current average has increased by 48.35% from the previous average price target of $25.75.
Exploring Analyst Ratings: An In-Depth Overview
The analysis of recent analyst actions sheds light on the perception of Dianthus Therapeutics by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Steven Seedhouse | Raymond James | Raises | Outperform | $51.00 | $34.00 |
| Maury Raycroft | Jefferies | Raises | Buy | $39.00 | $22.00 |
| Laura Chico | Wedbush | Raises | Outperform | $33.00 | $24.00 |
| Alex Thompson | Stifel | Announces | Buy | $44.00 | - |
| Laura Chico | Wedbush | Raises | Outperform | $24.00 | $23.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Dianthus Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Dianthus Therapeutics compared to the broader market.
- Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Dianthus Therapeutics's stock. This examination reveals shifts in analysts' expectations over time.
For valuable insights into Dianthus Therapeutics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on Dianthus Therapeutics analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Discovering Dianthus Therapeutics: A Closer Look
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
Dianthus Therapeutics: A Financial Overview
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Decline in Revenue: Over the 3 months period, Dianthus Therapeutics faced challenges, resulting in a decline of approximately -61.11% in revenue growth as of 31 December, 2023. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Dianthus Therapeutics's net margin is impressive, surpassing industry averages. With a net margin of -2311.38%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Dianthus Therapeutics's ROE stands out, surpassing industry averages. With an impressive ROE of -6.08%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Dianthus Therapeutics's ROA excels beyond industry benchmarks, reaching -5.68%. This signifies efficient management of assets and strong financial health.
Debt Management: Dianthus Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.0.
Analyst Ratings: What Are They?
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.